Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Shire's CEO is savoring a personal victory after Phase III data for lanadelumab in acute HAE replicated impressive Phase Ib trial results that underpinned his 2015 decision to buy Dyax.
Lars Fruergaard Jørgensen, Novo Nordisk's CEO, says the group's pledge on price transparency, goals for improved outcomes and experimental use of digital health are commercially linked.
The French pharma under its American CEO plans to transform itself through R&D and M&A, and promises to launch at least one new drug or new valuable indication every year - "forever".
Novo Nordisk's new CEO says bureaucracy and centralized control hinder sales growth, so one of his three top priorities is to give regional centers more commercial autonomy.
By adding another AI deal to Sanofi's innovation quiver, the French group says it's widening its hunt to find single molecules that offer dual or multi-specific targeting to fight disease.
Sanofi hopes to use Exscientia's artificial intelligence (AI) platform to develop bispecific-small-molecule drugs for diabetes and associated metabolic conditions.